<DOC>
	<DOCNO>NCT00468559</DOCNO>
	<brief_summary>The purpose study look improvement day dose esomeprazole reduce sign symptom infant gastroesophageal reflux disease ( GERD ) . This research study consist screen , open-label , double-blind treatment withdrawal phase . The screen phase ensure patient eligibility . No study medication dispense screen phase . During open-label phase , patient administer esomeprazole 2.5mg , 5.0mg 10.0mg base his/her weight . During double-blind phase , patient administer either his/her open-label dose placebo . Double-blind mean neither physician , parent , patient know patient take esomeprazole placebo . The patient equal chance receive esomeprazole placebo .</brief_summary>
	<brief_title>Phase 3/Safety &amp; Efficacy Esomeprazole Infants</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>patient ' parent must sign informed consent prior begin studyrelated procedure ( accord local regulation ) patient must symptoms study entry clinical diagnosis suspect GERD , symptomatic GERD , GERD proven test call endoscopy , test use long tube insert body diagnostic exam patient use PPI ( proton pump inhibitor ; use reduce amount acid stomach ) within 7 day enrollment open label treatment phase ( Day 0 ) patient history acute lifethreatening event</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>neonate</keyword>
</DOC>